CHOICES = Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
Study title
CHOICES = Imatinib Mesylate With or Without Hydroxychloroquine to Eliminate Malignant Stem Cells in Patients With Chronic Myeloid Leukemia [Europe]
Scientific title
A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR) (EudraCT 2009-014373-41, ClinicalTrials.gov NCT01227135)
Type of study
Treatment optimization trial
Current status
No longer recruiting
What is the purpose of the study
This trial is conducted to analyze the benefits and side effects of giving imatinib mesylate with or without hydroxychloroquine in patients with chronic myeloid leukemia. Patients will receive treatment for up to 12 months during the study period and possibly for up to 12 months during the follow-up period.
Key inclusion criteria
Chronic myeloid leukemia (CML) in chronic phase (CP)
Potential participants should have received imatinib mesylate for at least 1 year, and received a stable dose for at least 6 months. They should have achieved at least major cytogenetic response (MCyR) and continue to be BCR/ABL-positive by quantitative polymerase chain reaction (Q-PCR).
Key exclusion criteria
Where can I find additional information
Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)
Study sponsor
NHS Greater Glasgow and Clyde
Funded by Medical Research Council and supported by Cancer Research UK Trials unit Glasgow
Scientific lead / contact
Lynn McMahon
University of Glasgow
Principal investigator
Holyoake, Prof. Dr. Tessa
Gartnavel General Hospital
Institut of Cancer Sciences
Study centers / principal investigators
United Kingdom
Glasgow
Gartnavel General Hospital
Institut of Cancer Sciences
Prof Dr Tessa Holyoake
Leeds
St James University Hospital Leeds
Dr Graeme Smith
Liverpool
Royal Liverpool University Hospital
Prof Richard E. Clark
London
Addenbrookes Hospital
Dr Brian Huntley
Imperial College London
Dr David Marin
Nottingham
Nottingham University Hospital
Dr Jenny Byrne
France
Lyon
Hospices Civils de Lyon
Dr Franck Nicolini
Germany
Uniklinik RWTH Aachen
Klinik für Onkologie, Hämatologie und SZT
Prof. Dr. med. Steffen Koschmieder
Universitätsklinik Hamburg-Eppendorf
PD Dr. med. Philippe Schafhausen